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Abstract
Background: Cardiovascular disease (CVD) is a major cause of disability and premature death. Despite European
guidelines advocating the use of medical therapies in CVD, many patients still do not achieve the guideline-
recommended treatment, which highlights the need for change and innovations in this field. This requirement has
been widely recognised by the national ministries of health, several European cardiology societies, and the
European Parliament, who support the initiation of strategies to improve and promote cardiovascular health.
Discussion: One of the key risk factors to recurrent cardiovascular events is the lack of adherence to medication
and this has been added to the agenda of the European Commission. With the intention to improve treatment
adherence in CVD, polypills have been investigated and numerous studies demonstrate that they significantly
improve medication adherence, which contributes to the improvement of health outcomes. In Europe, the first
cardiovascular polypill, developed by a public-private partnership (CNIC-Ferrer), recently became available for
general prescription as a therapy for CVD prevention. This polypill significantly improves adherence, preventing fatal
and non-fatal cardiovascular events, and appears to be a cost-effective strategy to improve sustainability of the
health care systems in CVD.
Conclusions: Given the importance of urgent and simple solutions to restraining the pandemic nature of CVD, the
polypill approach should therefore be considered by physicians and public health systems as an available and
innovative option to improve cardiovascular health.
Background
Cardiovascular disease (CVD) is a major cause of
disability and premature death worldwide. Despite
European and American guidelines advocating the
use of medical therapies in CVD, many patients still
do not achieve the guideline-recommended treat-
ment, due to several reasons including poor or non-
adherence to the prescribed therapy or high medication
burden. As such, there is a clear need for change and
innovation in this field.
This need has been widely recognised in political, sci-
entific and patient communities in their support of the
initiation of strategies to improve and promote cardio-
vascular (CV) health.
One of the key risk factors to recurrent CV events is
the lack of adherence to medication and this has been
added to the agenda of the European Commission. With
the intention to improve treatment adherence and
strengthen comprehensive CVD prevention plans, sev-
eral approaches and interventions have been analysed,
such as the use of Dual Antiplatelet Therapy (DAPT), as
well as different tactics to modify behavioural risk fac-
tors. There have, however, only been few advances in the
field of drug treatment aimed at enhancing treatment ef-
fectiveness. In particular, polypills have been investigated
in the CVD field and numerous studies demonstrate that
they significantly improve medication adherence, which
contributes to the improvement of health outcomes.
This article analyses the issue of poor and non-
adherence to medication as a risk factor for CVD pre-
vention and focuses on the polypill therapy as an
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effective approach to help reduce the number of recur-
ring CV events in Europe.
Discussion
Epidemiology and burden of CVD in Europe
It has been widely demonstrated that CVD is a major
cause of disability and premature death worldwide [1].
An estimated 17.5 million people died in 2012 as a con-
sequence of CVD [2], and it is expected that this figure
will increase by 2030, reaching 23.3 million deaths dir-
ectly related to CV events [1].
Looking at a regional level, CVD is the leading con-
tributor to mortality in the 53 countries of the World
Health Organization (WHO) Europe Region, causing al-
most 4.1 million deaths each year, which means 46 % of
all deaths in Europe. In the European Union (EU) alone,
CVD causes more than 1.9 million deaths annually
and the geographical distribution of this figure across
Europe reflects particularly higher rates of deaths in
the northern countries over the southern nations. In
all countries, death rates for coronary heart disease
(CHD) are higher in males than females [3].
The global burden of CVD is led by CHD and stroke,
which have been identified as the first and third lead dis-
eases for disability-adjusted life-years, as a sum of years
of life lost due to premature death and years of life lived
with disability, worldwide [4]. For Europeans, in addition
to being the lead cause of mortality, CVD also makes a
substantial contribution to morbidity rates. Overall,
CVD is estimated to cost the European economy almost
EUR 196 billion a year. Of the total spending, around
54 % is directly associated to health care costs, 24 % to
productivity losses and 22 % is a consequence of the in-
formal care of people with CVD [5].
The importance of secondary prevention in CVD
Some studies showed that the progresses made in secur-
ing the stabilisation of patients after a CV event, such as
myocardial infarction (MI), have largely contributed to
the prevalence of CHD as a chronic disease. Conse-
quently, recurrent CVD events are common among
people who have previously been diagnosed with an
MI, with rates found as close to 50 % for any CVD
event [6, 7] or subsequent revascularisation [8] during
the first year after suffering an MI. It has also been
demonstrated that up to 75 % of patients have a recur-
rent event within 3 years after suffering a MI [7, 9]. In
addition, patients with a history of acute myocardial in-
farction (AMI) are at least five to six times more likely
to die of CV causes within a year [10].
It is therefore essential to understand and to consider
the implications for the long-term prognosis of the con-
dition, both for survival and the risk of recurrence [11].
In this regard, guidelines have suggested behavioural risk
factors as critical for the progression of CVD in patients,
such as smoking, unbalanced diet, lack of physical activ-
ity and harmful use of alcohol [12]. In addition, medical
risk factors, such as no revascularization procedures, the
presence of comorbidities, as well as the lack of adher-
ence to prescribed medication, have also been shown to
be associated with recurrent CV events [13].
Although modifying patients’ lifestyle and behaviours
could partly reduce the recurrence of CV events, [12], a
large body of evidence supports the use of medical ther-
apies as the most effective approach to secondary pre-
vention of CVD [14, 15]. The combined use of aspirin,
angiotensin-converting-enzyme (ACE) inhibitors and
lipid-lowering therapies has been proven [16, 17] to be
highly effective in lowering the risk of secondary CV
events. Indeed, it has been estimated that about two-
thirds to three-quarters of future vascular events could
be prevented when using these drugs together [15], and
it also leads to a large reduction of CVD-related deaths
[14]. Given this evidence, decreasing the recurrence of
CV events has become a global priority [18], and, ac-
cordingly, European guidelines have openly and strongly
advocated for the use of medical therapies in the preven-
tion of secondary CV events and in particular for the
use of polypills to increase adherence [19].
However, while guidance from experts is clear, recent
studies have demonstrated a suboptimal use of medi-
cines targeted for the prevention of recurrent CV events,
showing that only 43 % of patients with acute coronary
syndrome (ACS) are actually prescribed with optimal
treatment for secondary prevention [20, 21]. As a conse-
quence, experts have made a call to action, which high-
lights the need to improve clinical prevention particularly
in primary care, where it may be beneficial to enhance the
quality of the relationship between healthcare providers
and patients to ensure that they benefit from fully avail-
able knowledge [10].
In addition, the latest EUROASPIRE study [22], a
cross-sectional study undertaken across 78 centres in 24
European countries, demonstrated that a large majority
of coronary patients does not follow the recommenda-
tions set by guidelines on modifying their behavioural
patterns towards a balanced and healthy lifestyle. There-
fore, risk factor control and therapeutic targets are not
achieved as required to manage the prevention of recur-
rent CV events properly.
Adherence to medication has been widely identified as
a risk factor to the recurrence of CVD. Good adherence
is associated with positive health outcomes and poor ad-
herence to treatment actually increases the likelihood of
suffering a recurrent CV event [23, 24]. A recent study
further showed that low-risk, intermediate risk and
high-risk patients with AMI in the year following dis-
charge, present poor adherence rates to prescribed
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therapies: 61.5, 57.9 and 45.9 % respectively [25]. Sup-
porting this finding, a previous meta-analysis also dem-
onstrated that compliance with the medication was met
only in 66 % of CVD cases [26].
A direct link between adherence to treatment and
health outcomes has been repeatedly reported and poor
compliance was documented to be associated with con-
siderable worsening of the condition [27], rehospitalisa-
tion, morbidity and mortality [28]. In order to reduce
low adherence rates, many experts have studied the link
between compliance with medication and pill burden as
a potential key to modifying treatment outcomes
through adapting patient’s behavioural patterns. As a re-
sult, it has been shown that the prescribed number of
doses per day is inversely correlated to adherence, and
simpler and less frequent dosing regimens usually drive
better compliance rates [29]. This data therefore sup-
ports the view that optimization of treatment regimens
and increased compliance can help to prevent the recur-
rence of CV events [22].
Given the evidence, it is clear that medication adher-
ence in CVD prevention remains a challenge for pa-
tients and healthcare providers. Lack of compliance is
not only associated with a lower quality of life and poor
health outcomes, but also has socio-economic impact
and generates elevated costs to healthcare systems. In
the EU, the number of deaths associated with miss-
dose and non-adherence to prescribed medication in
general is estimated to be approximately 194,500 per
year and non-adherence is estimated to cost the EU
EUR 125bn annually [30].
The need for change and innovation in CVD prevention
The need for new and more effective delivery of evi-
dence based preventive treatments to patients is increas-
ingly recognised by Governments of Member States of
the EU, the European Society of Cardiology (ESC),
National Cardiac Societies, the European Heart Network
(EHN), National Heart Foundations and the Union of
European Medical Specialists Union (Européenne des
Médecins Spécialistes, UEMS) Cardiology section. The
importance of strengthening of comprehensive CVD
prevention plans and the certainty that effective mea-
sures, policies, and interventions would be in place in all
European countries, was adopted in 2005 in the
Luxembourg Declaration [31]. In 2007, the European
Parliament also adopted by a large majority a ‘Resolution
on Action to Tackle Cardiovascular Disease’, calling on
the Commission and Member States to adopt or review
national public health strategies to include the promo-
tion of strategies on CV health amongst others [32].
More recently, the MEP Heart Group, in collaboration
with the WHO and supported by the ESC and the
EHN, launched the Pledge for Cardiovascular Health,
encouraging members of the European Parliament
(MEPs) to show their support for CV health and com-
mitting them to consider the impact of CV health when
voting on EU legislation and to support national strat-
egies to promote CV health [33].
Recent innovations in the prevention of CV events
In line with these calls for action, clear advances in the
field were made and some of the key progresses in CVD
prevention in 2015 were summarised [34]. These include
the introduction of a comprehensive personalised pre-
ventive strategy to reduce modifiable risk factors, includ-
ing lifestyle and dietary habits. Among the main
outcomes observed through the control and close
follow-up of behavioural factors in patients at high risk
of CVD, a significant reduction in events was demon-
strated over a 5-year period [35].
Advances in the treatment of CVDs from previous
years that target non-modifiable risk factors include the
use of Dual Antiplatelet Therapy (DAPT), which is usu-
ally prescribed after a heart attack or stent placement to
keep the vessels open and to prevent future heart attacks
[36]. The administration of DAPT for 12 months in pa-
tients with ACS, was shown to improve the outcomes
when compared to administrating aspirin alone for the
prevention of recurrent events [37].
Despite these calls for action, there have only been a
few clear advances in drug treatment in the field in re-
cent years.
The polypill approach, which combines several medi-
cines that simultaneously control several risk factors or
disease mechanisms in a single pill, is one of those strat-
egies that has, in recent years, progressed in the CVD
field. The concept was introduced by Wald and Law in
2003, who described a fixed-dose combination strategy,
containing six components, and claimed that the admin-
istration of this polypill to each individual over 55 years
old would reduce the incidence of CVD by more than
80 % [38]. Since then, several polypill concepts have
been proposed, including the ‘vaccination approach’,
which refers to the use described by Wald and Law, as
well as the use in primary and secondary CVD preven-
tion [39]. As with most treatments, the benefits, as well
as the drawbacks of the polypill, have been widely dis-
cussed [39]. Some argued that the originally proposed
estimated risk reduction potential of the polypill could
be too optimistic and that many patients would remain
undertreated. Concern about potential adverse effects
related to some of the polypill’s monocomponents also
exist, and it has been argued that side effects from one
of the components could lead to discontinuation of
treatment. This could then result in the loss of all the
benefits of the other components included in the poly-
pill [39]. Nonetheless, despite these concerns, the
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potential of the polypill to improve the management of
CVD risk factors has been recognised by several expert
panels, including the WHO and the Combination
Pharmacotherapy and Public Health Research Working
Group, who consider research in this area an important
breakthrough [39].
The polypill approach in CVD prevention
Several drug classes (antiplatelet agents, beta-blockers,
renin-angiotensin system blockers and statins) exist, and
have been shown in multiple large cardiovascular out-
come trials to reduce the risk of events when used in the
setting of CVD prevention [19]. However, implementing
preventative treatment in routine care has been less suc-
cessful and several barriers exist; notably, insufficient
prescription of therapies to patients and poor adherence
to medicines by patients.
The polypill approach has been advocated to help
overcome some of these barriers to CVD prevention
[19]. To date, three polypills have been investigated for
CVD prevention. The CNIC-Ferrer polypill is, however,
the only one for which a marketing authorisation has
been granted in the EU, in other European countries and
in Latin-America so far [40].
The effect of polypills on treatment adherence has
been studied in detail in recent years. As such, results
from the UMPIRE, IMPACT, Kanyini GAP, and FOCUS
trials showed that the polypill significantly increases ad-
herence to treatment when compared to administering
either the individual drugs separately [41] or when com-
pared to usual care [42–44].
In more detail, the randomised, open-label UMPIRE
trial among people with established CVD or at risk of
CVD demonstrated that the use of a fixed-dose combin-
ation (FDC) therapy significantly improved adherence to
treatment at 15 months, as well as leading to statistically
significant improvements in systolic blood pressure
(SBP) and low-density lipoprotein (LDL) cholesterol
[42]. In line with this, the open label randomised control
trial IMPACT (IMProving Adherence using Combin-
ation Therapy) assessed the effects of FDC treatment on
adherence and risk factor control, compared with usual
care of patients at high risk of CVD in primary care.
The authors showed that adherence to recommended
medications was greater among FDC than usual care
participants at 12 months (81 % versus 46 %). A post-
trial survey of this study further revealed a high accept-
ability of the FDC therapy for general practitioners and
patients [43]. Similarly, another randomised clinical trial
conducted in 623 patients with established CVD or at
high risk of CVD – the Kanyini GAP trial – compared
the polypill to usual care and showed that patients
treated with the polypill were more adherent to their
treatment than patients at usual care after a follow up at
18 months [44]. The three trials described above were
part of the Single Pill to Avert Cardiovascular Event
(SPACE) collaboration, which compared polypill-based
care with usual care. A prospective, individual partici-
pant data meta-analysis of these three controlled trials
was published late 2015, showing that the polypill ther-
apy significantly improved adherence, SBP and LDL-
cholesterol in high risk patients when compared with
usual care, especially among those patients who were
under-treated at baseline [45].
Moreover, the cross-sectional FOCUS study (Fixed-
Dose Combination Drug for Secondary Cardiovascular
Prevention) assessed the effect on adherence of treat-
ment with the polypill in comparison to treatment with
its separate monocomponents in 695 adult patients fol-
lowing a MI. After 9-months of follow-up, the percent-
age of adherent patients in the polypill group was
significantly increased by approximately 22% when com-
pared to the group receiving the separate components of
the polypill [41].
A more general meta-analysis assessing patients with
acute and chronic diseases also examined the impact of
reduced frequencies of oral therapies from multiple- to
once-daily dosing schedule on adherence. It suggested
that across acute and chronic disease states, adherence
to therapies might be improved by reducing dosage fre-
quency. The study further suggested that this increase in
adherence may result in subsequently lower healthcare
costs [46]. In line with this, several other articles also
found that a simpler and less frequent dosing regimen
results in improved compliance across a variety of thera-
peutic classes [29], and adherence rates decrease when
dosing frequency increases [47].
By reducing the complexity of the medication regimen,
the polypill can also help overcome some of the add-
itional risks and problems associated with polypharmacy.
Polypharmacy after a CV event is common and may
pose risks, such as adverse drug interactions, accidental
overdosing and medication non-adherence, that origin-
ate from the difference in medication schedule and dos-
age [48]. Especially in elderly patients, polypharmacy
may pose a problem due to the patient’s strong belief in
their medication and self-medication, which can lead to
adverse drug interactions and other mistakes in their
drug intake [49, 50]. By reducing the pill burden and by
improving medication compliance, the polypill has thus
been suggested as a way to help overcome some of the
issues related to polypharmacy [51, 52], as well as trans-
lating into better CV outcomes.
Interestingly, numerous studies have demonstrated
that patients also consider polypills as more convenient
and prefer having to take one single medicine instead of
several individual medicines. Indeed, a recent study
assessing the influence of polypill-based treatment
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attributes and patient characteristics on preferences for
CVD preventive treatment showed that treatment pref-
erence decreased with tablet number. The discrete
choice experiment further demonstrated that patients
value and are willing to pay a premium for each tablet
reduction [53].
The polypill provides physicians with an improved tool
to meet the progressively more stringent secondary pre-
vention guidelines from the ESC and other medical soci-
eties. This is significant as inadequate prescription of
medicines remains a substantial gap in the coverage of
secondary interventions for the prevention of CVD, as
demonstrated by the findings from the WHO study on
Prevention of REcurrences of Myocardial Infarction and
StrokE (WHO-PREMISE) [10], the Antiplatelet Treat-
ment Observational Registry (APTOR) [20], SURF [21],
and EUROASPIRE IV study [22].
Despite the impressive number of potential benefits
of the polypill strategy in CVD prevention, its use is
relatively novel. One concern of polypill sceptics is that
patients will regard the polypill as an excuse to poten-
tially replace efforts to promote healthy lifestyles [54].
Rather than replacing them, lifestyle modifications
should be initiated simultaneously with drug therapy as
the benefits associated are additive and complement
each other in the prevention of CVDs. Based on the
WHO’s recommendations, the polypill approach could
be a ‘best buy’ as a primary healthcare approach for
CVD prevention [12].
The CNIC-Ferrer polypill project
Polypill is now a reality because the first of its kind has
been released to the market in Europe. The CNIC-Ferrer
polypill project is the European polypill developed as a
therapy for secondary CVD prevention. It was inspired
by the needs of most patients with a previous heart dis-
ease, guideline recommendations outlined above, and
negative health outcomes originating from lack of adher-
ence. It was developed through a public-private strategic
partnership between the Centro Nacional de Investiga-
ciones Cardiovasculares (CNIC), Spain, and Ferrer,
Spain. The research was supported by European funding
from the 7th European Framework Programme and
Horizon 2020 to help overcome the unmet clinical need
in CVD prevention [55].
To date, the CNIC-Ferrer polypill strategy is the first
and only polypill approved in 15 European countries
[56], already commercialised and reimbursed in several
ones, commercialised in various Latin American coun-
tries as well as under registration in some Middle-East
and North African (MENA) and Asia-Pacific (APAC)
countries. The polypill is expected to simplify the ther-
apy by reducing the patient’s pill burden, which may
improve adherence to secondary prevention medications
and decrease further CV events in the long term.
This polypill consists of an angiotensin-converting en-
zyme (ACE) inhibitor (ramipril), a statin (atorvastatin) and
an aspirin, at dosages established to achieve the best bal-
ance safety/benefit that has been proven to prevent CVD
events. Moreover, the use of the polypill components in
patients who have suffered a CV event is commended by
ESC [19], American Heart Association (AHA) [57], and
WHO guidelines [18]. In addition, the CNIC-Ferrer poly-
pill has proven bioequivalence compared with each of its
original mono-components and holds a patent for its in-
novative galenic formulation [56].
By combining three medicines recommended for the
secondary prevention of CV events in a once-daily cap-
sule, the polypill was shown to significantly increase ad-
herence in patients following a CV event when
compared to administering the three drugs separately
[41]. This increase in adherence has been suggested to
lead to a reduction of recurrent CV events and its asso-
ciated costs, which originate from rehospitalisation,
long hospital stays and revascularization procedures
[12, 53, 58]. Indeed, recently published studies demon-
strated that the use of a polypill appeared to be a cost-
effective strategy to prevent fatal and non-fatal CV
events in the UK [59], Spain [60], and Mexico [61].
A pan-European perspective
One of the priorities of the European Commission is
to contribute to the improvement of adherence to
medical plans and medication [62]. Furthermore, in
the broader European CVD environment, efforts
continue to deliver patient access to the most com-
pelling, evidence-based preventative therapies. The
European Commission’s (EC) Horizon 2020 frame-
work programme, which is making EUR 80 billion of
public funding available to researchers between 2014
and 2020 [63] alongside private sector investment, is
actively investing in research and innovation for
long-term chronic diseases, including CVD [58, 64],
and has been highlighted as a critically-important ve-
hicle to innovate for improved patient outcomes. Of
note, amongst other innovations in chronic diseases,
the potential role of polypill-based strategies in CVD
prevention is also being investigated within the Horizon
2020 framework [55].
There is a pan-European fiscal challenge facing the
management of non-communicable diseases (NCDs),
such as CVD. Heart disease, stroke and diabetes cause
significant loss of national income each year in the
world’s most populous nations. Economic analysis sug-
gests that each 10 % rise in NCDs is associated with
0.5 % lower rates of annual economic growth [12].
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Public-private partnerships to unlock improved CVD
outcomes
The International Monetary Fund (IMF) has highlighted
public-private partnership as a very relevant way to im-
prove R&D and innovation [65]. These types of partner-
ships have already proven successful in several therapeutic
areas. Challenging public-health diseases such as malaria
and sleeping sickness has demonstrated not only the im-
portance, but how crucial is the role of a such public
health-oriented R&D in order to ensure timely and effect-
ive delivery of new drugs to face very important public-
health diseases [66, 67].
The CNIC-Ferrer polypill project discussed in this
paper is a recent example of a successful collaboration
between publicly-funded health bodies and the industry
sector to deliver improved therapeutic strategies and so-
lutions in chronic disease areas. CNIC, supported by the
Ministry of Economy of the Spanish Government, aims
to expedite CV research in Spain and to ensure funding
is made available to conduct biomedical research with a
focus on prevention rather than treatment, where pos-
sible. Its objectives are aligned with the EC Horizon
2020 vision of reducing ‘red tape’ in a bid to ensure
Europe produces world-class science, removes barriers
to innovation and makes it easier for the public and pri-
vate sectors to work together. The author group of this
paper believe the CNIC-Ferrer partnership provides an
appealing and innovative model for therapeutic discov-
ery and development on the continent.
A call to action
Combination therapy has become the standard for
treating several relevant major communicable diseases
such as HIV/AIDS, TB and malaria, and has recognised
benefits in slowing resistance, improving clinical out-
comes and facilitating logistics [68]. Other non-
communicable diseases such as hypertension [69] and
diabetes [70], have also been proven to benefit from
combination therapy.
The European Medicines Agency (EMA) recognises
that fixed-dose combinations of medicinal products have
been increasingly used due to the benefit of the com-
bined effects of active substances given together and has
issued a guideline on the clinical development needed
for ‘fixed dose combination’ medicinal products depend-
ing on the intended indication [71].
CVD prevention remains one of the key medical chal-
lenges affecting European populations, and effective,
simple solutions have a key role to play in restraining
the pandemic nature of the disease [54]. The polypill ap-
proach to CV prevention, in particular, has shown sig-
nificant potential in the absence of a plethora of
alternative strategies which do not rely on a multi-drug
approach. It has already shown an adherence benefit,
and can be sustained across multiple geographies.
Additional research is ongoing; however such is the
scale of the public health challenge in CVD that health
professionals should consider the polypill approach
among the available options (in harmony with lifestyle
modifications) in the context of individualised patient
need. The authors also urge European public health
systems to consider endorsing this valuable innovation
for their patients.
Moreover, in view of the public-health interest to as-
sure adherence to treatment in relevant communicable
and non-communicable diseases, additional programmes
on adherence and more research should be undertaken
and funding provided to gather evidence, in order to
healthcare professional to tackle CVD burden by adopt-
ing innovative healthcare interventions including the
polypill strategy. Last but not least, European patient as-
sociations should envisage educational training to pro-
mote patients’ awareness of cardiovascular risk and
disease while engaging them in the adherence to healthy
lifestyle habits and pharmacological treatment with the
final objective to control risk factors and empower them.
The authors’ call to action is therefore directed to
payers, patient associations, industry, research funders,
regulators, and healthcare professionals, to ensure that
polypills are developed, made available and accessible to
patients in diseases than benefit from improving the ad-
herence to their treatments.
Conclusions
Following an analysis of the current context of CVD in
Europe, a need for innovative and effective interventions
in the prevention of secondary CVD was highlighted.
In order to cope with poor and non-adherence to
treatment, which has been widely identified as a key risk
factor in the prevention of CVD, the polypill approach
has been demonstrated to be an effective innovation to
improve CVD outcomes. Several studies have shown
that a simpler and less frequent dosing regimen results
in improved compliance to medication across a variety
of therapeutic classes and that adherence rates decrease
when dosing frequencies increase. In line with this, the
polypill, which reduces the complexity of the medication
regimen, was demonstrated to help increase medication
adherence in CVD patients, improving health outcomes.
In light of the epidemic scale of CVD, the first CV
polypill was recently made available by European
decision-makers as a therapy for CVD prevention in
Europe. This polypill was shown to significantly improve
adherence and reduce the number of CV events. It also
appeared to be a cost-effective strategy to prevent fatal
and non-fatal CV events.
It is clear that CVD prevention remains to be one of
the key medical challenges in Europe, and effective,
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simple solutions are needed to restrain the pandemic na-
ture of the disease. The polypill approach has a signifi-
cant potential in the context of CVD prevention and
should be considered an available, valuable innovation
by healthcare professionals, patients and public health
systems in order to improve CV health.
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